Coya Therapeutics Inc. (NASDAQ:COYA) on Tuesday announced results from a study designed to evaluate the effects of COYA 303 ...

ProKidney shows strong Phase 2 CKD data, FDA support, and cash runway, with key readouts ahead despite single-asset risks.

Absci is developing ABS-101, an anti-TL1A antibody with potential in ulcerative colitis, Crohn's disease, and other ...

Higher activity of PGC-1α enables brown fat cells in females to achieve thermogenic activity and energy expenditure compared ...

While our understanding of Alzheimer’s disease is far from complete, the latest therapies, and others in more than 100 ...

A Brandon University graduate student has been awarded a $20,000 Research Manitoba Master’s Studentship for investigating how ...

A new study reveals that berberine, a natural compound from traditional Chinese medicine, can improve brain function and ...

The open-angle glaucoma market is projected to grow steadily, driven by the rising global prevalence of glaucoma due to aging populations and increasing awareness of early diagnosis. Additionally, the ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic ...

Higher activity of PGC-1α enables brown fat cells in females to thermogenic activity and energy expenditure compared to males ...

Alzheimer’s disease has proved to be a tricky target, and researchers and drug developers have been pursuing effective ...